Every 8-K that DOCGO INC (DCGO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DCGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DCGO filings page.
DocGo Inc. announced a definitive agreement to acquire virtual care provider Hicuity Health through a stock-for-equity transaction and assumption of Hicuity’s debt. A DocGo subsidiary will merge with Hicuity, which will become a wholly owned subsidiary, in a transaction intended to qualify as a tax‑free reorganization. Merger consideration includes DocGo common stock equal to 2.0% of fully diluted shares at closing plus potential 3.5% additional “Earnout Shares,” which vest only if DocGo’s stock reaches a specified market‑cap threshold; otherwise they are forfeited. DocGo will also assume approximately $52 million of Hicuity term loans held by Perceptive Advisors, now expected to mature in December 2029, and Perceptive has committed up to $50 million of new senior secured term loans in three tranches.
For the quarter ended June 30, 2026, DocGo reported revenue of $73.4 million versus $80.4 million a year earlier, with the decline entirely from the wind‑down of migrant‑related programs; excluding those programs, revenue grew 19% year over year. GAAP gross margin was 26.9%. Net loss was $18.0 million and adjusted EBITDA was ($6.3) million. Unrestricted cash was $25.2 million as of June 30, 2026. Hicuity generated approximately $65 million of trailing‑12‑month revenue and $4.5 million of adjusted EBITDA. DocGo now guides full‑year 2026 revenue to $305–$310 million and adjusted EBITDA to ($17)–($22) million, excluding any Hicuity contribution.
DocGo Inc. reports that Nasdaq has granted additional time to regain compliance with the exchange’s minimum bid price rule. The company now has until January 25, 2027 to meet the Nasdaq Listing Rule 5550(a)(2) requirement that its common stock close at or above $1.00 per share for at least 10 consecutive business days. If this condition is met before the deadline, Nasdaq staff will confirm that the company has returned to compliance.
DocGo states that it will monitor its share price and evaluate options to regain compliance, including a possible reverse stock split. At the June 16, 2026 annual meeting, stockholders approved an amendment authorizing a reverse split at a ratio between 1-for-5 and 1-for-10, to be implemented at the board’s discretion.
DocGo Inc. extended the expiration date of its existing share repurchase program from June 30, 2026 to December 31, 2026. The program continues to allow purchases of up to $26 million of common stock through open market or privately negotiated transactions and related methods. Repurchases may be funded from cash, future cash flow or borrowings, and the program can be modified, suspended or discontinued at any time.
DocGo Inc. held its 2026 annual stockholder meeting, where investors elected two Class II directors, Vina Leite and James M. Travers, to serve until the 2029 meeting. As of the April 20, 2026 record date, 98,778,413 common shares were entitled to vote.
Stockholders approved on a non-binding basis the compensation of the company’s named executive officers and authorized a reverse stock split at a ratio between 1-for-5 and 1-for-10, at the board’s discretion. They also ratified Urish Popeck & Co., LLC as independent auditor for the year ending December 31, 2026.
Proposed charter amendments to permit broader waivers of corporate opportunities and to add officer liability exculpation did not receive the requisite level of support, so the company’s charter was not amended for those items.
DocGo Inc. reported first quarter 2026 revenue of $75.6 million, down from $96.0 million a year earlier due to the wind-down of migrant-related programs. Excluding $35.0 million of prior-year migrant revenue, underlying revenue grew 19.3% to $75.6 million from $61.0 million, driven by virtual care and other mobile health services.
GAAP gross margin was 28.1%, with adjusted gross margin of 31.6%. The company posted a net loss of $16.7 million versus a $11.1 million loss last year, and adjusted EBITDA of negative $10.2 million compared to negative $3.9 million. Cash, cash equivalents, restricted cash and investments totaled about $59.9 million as of March 31, 2026, down from $68.3 million at year-end.
Medical Transportation Services revenue edged up to $51.9 million, while Mobile Health Services revenue declined to $23.6 million but more than doubled excluding migrant work. Management raised full-year 2026 revenue guidance to $300–$315 million and reiterated an adjusted EBITDA outlook of negative $5 to $10 million, citing strong demand for virtual care and home-based services.
DocGo Inc. announced that board member Stephen K. Klasko, MD will step down from the Board and his committee roles, effective at the conclusion of the 2026 Annual Meeting of Stockholders expected on June 16, 2026. His departure is not due to any disagreement with the company.
The Board appointed long-serving independent director Michael Burdiek as independent Chair of the Board, effective at the same time. Jim Travers will replace Dr. Klasko on the Audit and Compliance Committee and the Nominating and Corporate Governance Committee. On April 21, 2026, the Board also formed a special committee of three directors, chaired by Mr. Burdiek, to assist management in identifying corporate efficiencies and cost reduction opportunities to help accelerate profitability.
DocGo Inc. reported fourth quarter and full-year 2025 results, raised its 2026 outlook, and began exploring strategic alternatives to maximize shareholder value. Full-year 2025 revenue was $322.2 million, down from $616.6 million in 2024 entirely due to the wind-down of migrant-related programs, which fell from $373.5 million to $69.6 million. Excluding these programs, core businesses grew, including Medical Transportation revenue rising to $200.8 million and Mobile Health Services reaching $121.4 million. The company swung to a 2025 net loss of $196.4 million, including non-cash impairments of $30.6 million in intangible assets, $58.2 million in goodwill, and $5 million on an equity investment. Adjusted EBITDA shifted from a $60.3 million profit in 2024 to a $28.6 million loss in 2025. In the fourth quarter, revenue was $74.9 million and adjusted gross margin was 32.5%. Cash and cash equivalents, including restricted cash and investments, totaled about $68.3 million as of December 31, 2025. For 2026, DocGo now expects revenue of $290–$310 million with an adjusted EBITDA loss of $5–$10 million, improved from prior guidance, and management believes profitability is achievable in the second half of 2026.
DocGo Inc. has been notified by Nasdaq that its stock no longer meets the exchange’s $1.00 minimum bid price requirement. Nasdaq reviewed closing bid prices between December 9, 2025 and January 23, 2026 and found the shares below the threshold, triggering a compliance notice.
The company keeps its current Nasdaq Capital Market listing for now and has until July 27, 2026 to lift its closing bid to at least $1.00 for ten consecutive business days. If it still falls short, DocGo may seek a second 180-day grace period, potentially including a reverse stock split to restore compliance.
DocGo Inc. extended the expiration date of its existing share repurchase program from December 31, 2025 to June 30, 2026. The program continues to authorize the company to repurchase up to $26 million of its common stock.
DocGo may buy shares from time to time through open-market purchases, privately negotiated transactions, or arrangements such as Rule 10b5-1 trading plans and accelerated share repurchase programs, during trading windows when it is not in possession of material non-public information. Repurchases may be funded with existing cash and cash equivalents, future cash flow, or proceeds of borrowings or debt offerings, and the program can be modified, suspended, or discontinued at any time.
DocGo Inc. (DCGO) furnished its earnings materials for the quarter ended September 30, 2025. The company issued a press release and provided supplemental non-GAAP metrics, including adjusted gross margin and adjusted EBITDA contribution margin, as supporting materials.
Management scheduled a conference call and webcast at 5:00 p.m. Eastern Time on November 10, 2025 to discuss results. The materials were furnished, not filed, and include Exhibit 99.1 (Press Release) and Exhibit 99.2 (Non-GAAP Financial Information).
DocGo Inc. filed an amended Form 8‑K to attach the Merger Agreement for its completed acquisition of SteadyMD, Inc. via subsidiary Ambulnz Holdings, LLC. The transaction totals up to $25 million, consisting of $12.5 million in cash paid at closing and up to $12.5 million as a contingent earn‑out payable in cash or equity at the Company’s election, tied to performance conditions. The closing payment is subject to customary post‑closing adjustments for working capital, debt, and transaction expenses.
Upon filing a Certificate of Merger on October 20, 2025, SteadyMD merged into STMD Merger Company, LLC, which survived; all shares, options, and warrants of the Acquired Company were canceled. This amendment adds the Merger Agreement as Exhibit 2.1 and does not change other prior disclosures.
DocGo Inc. announced that its wholly owned subsidiary, Ambulnz Holdings, completed the acquisition of SteadyMD, Inc. via a merger on October 20, 2025. The deal carries an aggregate purchase price of up to $25 million, including $12.5 million in cash paid at closing and up to $12.5 million in contingent earn-out, payable in cash or equity at the company’s election if specified performance conditions are met. The closing cash amount is subject to customary post‑closing adjustments for working capital, indebtedness, and transaction expenses.
Upon filing the certificate of merger, SteadyMD merged into a DocGo subsidiary with the subsidiary surviving, and all SteadyMD shares, options, and warrants were canceled under the agreement. DocGo will host a conference call and webcast on October 21, 2025 at 11:00 a.m. ET to discuss the transaction.